Articles

Lilly competitor gets backing on diabetes drug

Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.

Read More

Lilly plans another study for Alzheimer’s drug

Eli Lilly will launch another study of its possible Alzheimer's treatment solanezumab, a move that delays a regulatory decision on a drug that flashed potential to help patients with mild cases of the fatal disease.

Read More

Competing Alzheimer’s treatments facing long odds

Johnson & Johnson, Pfizer Inc. and Elan Corp are racing Indianapolis-based Eli Lilly and Co. to market the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms. Analysts say the potential drugs are long shots.

Read More

Notre Dame receives $5M for adult stem cell research

The university says the gift from an alumnus will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, in hopes of accelerating discovery of new treatments for heart disease, diabetes and some cancers.

Read More

Cancer tools help Roche with Alzheimer’s drug

Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.

Read More